Sputnik V labelled 'most efficient COVID-19 vaccine' as China manufacturing deal announced

19 April 2021

The Russian Direct Investment Fund (RDIF), the country's sovereign wealth fund, and Hualan Biological Bacterin have announced an agreement on production of more than 100 million doses per year of the world’s first registered vaccine against coronavirus Sputnik V, in China.

This amount of the vaccine will be sufficient to vaccinate more than 50 million people.

Kirill Dmitriev, chief executive of the RDIF, said: “Cooperation agreement with Hualan Biological Bacterin, one of the leading vaccine manufacturers of China, will help significantly increase the production capacities of Sputnik V. China is one of the key partners in production of the Russian vaccine, which is already used virtually in every part of the world to protect people’s health as Sputnik V has proved to be safe and highly effective.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK